Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial

Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial

Abstract Safe and effective new oral therapies for autoimmune, allergic, and inflammatory conditions remain a significant therapeutic need. Here, we investigate the human pharmacokinetics, pharmacodynamics (PDs), and safety of the selective, covalent Bruton's tyrosine kinase (BTK) inhibitor, re...

Full description

Saved in:
Bibliographic Details
Main Authors: Martin Kaul (Author), Peter End (Author), Maciej Cabanski (Author), Carole Schuhler (Author), Annamaria Jakab (Author), Magdalena Kistowska (Author), Arvind Kinhikar (Author), Alessio Maiolica (Author), Angela Sinn (Author), Rainard Fuhr (Author), Bruno Cenni (Author)
Format: Book
Published: Wiley, 2021-09-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items